Symvivo is a biotechnology company that specializes in the cancer gene therapy field. It develops bacTRL, a live cell probiotic-based gene delivery platform designed for the treatment of solid tumors. The platform technology can be applied to address oncological, cardiovascular, genetic, and infectious diseases.